SEATTLE, May 25, 2022 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, global HPAPIs and cytotoxic drugs manufacturing market is estimated to be valued at US$ 27.78 Billion in 2022 and is expected to exhibit a CAGR of 8.0% during the forecast period (2022-2030).
Key Trends and Analysis of the Global HPAPIs and Cytotoxic Drugs Manufacturing Market:
Key trends in the market include increasing product approvals, increasing prevalence of chronic diseases, increasing research and development activities, and inorganic growth activities such as collaborations, etc.
Key players are engaged in launching new products and this is expected to drive growth of the global HPAPIs and cytotoxic drugs manufacturing market over the forecast period. For instance, in March 7, 2022, Teva Pharmaceuticals, a subsidiary of Teva Pharmaceutical Industries Ltd. in the U.S., announced the launch of a first generic version of Revlimid (lenalidomide capsules) in the U.S. It is a prescription drug which is used to treat multiple myeloma in combination with other diseases.
Market players are indulged in expanding their manufacturing facility and this is expected to drive growth of the global HPAPIs and cytotoxic drugs manufacturing market over the forecast period. For instance, in July 2020, Helsinn Advanced Synthesis SA (HAS), a manufacturing subsidiary of Helsinn Healthcare that develops and manufactures active pharmaceutical ingredients (APIs), cGMP advanced intermediates, high potency APIs (HPAPIs), and anticancer compounds, announced the opening of its largest dedicated anticancer bay at its manufacturing plant in Biasca, Switzerland. Clinical and commercial anticancer APIs will be developed, analyzed, and manufactured at the new anticancer bay.
Request Sample copy of this Report @ https://www.coherentmarketinsights.com/insight/request-sample/1312
HPAPIs and Cytotoxic Drugs Manufacturing Market Report Coverage
| Report Attributes | Details |
| Market Size in 2022 | $27.78 Billion |
| Market Size Projection in 2030 | $51.53 Billion |
| CAGR (2022-2030) | 8.0 % |
| Largest Market | North America |
| Growth Drivers |
|
| Segmentation | By Drug Origin, By Drug Type, By Type of Pharmacological Molecule, and By Application |
| Regional Analysis | North America (US, Canada), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Europe (U.K, Germany, Italy, France, Spain, Russia and Rest of Europe), APAC (China, Japan, India, South Korea, Australia, ASEAN and Rest of Asia Pacific), ME (GCC Countries, Israel, and Rest of Middle East) & Africa (South Africa, North Africa and Central Africa). |
| Key Companies Covered | Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Lonza Group, CordenPharma International, Evonik Industries AG, Flamma Group, Merck KGaA, CARBOGEN AMCIS, Catalent, Inc., Piramal Enterprises Ltd., AbbVie Inc., Fareva Group, Cerbios-Pharma SA, Novasep, Ajinomoto Bio-Pharma, PCI Pharma Services, Sterling Pharma Solutions, Heraeus Holding, Polpharma Biologics, Helsinn Healthcare SA, Seqens, Cambrex Corporation |
Market players are focusing on inorganic activities, such as signing agreements, and this is expected to drive the growth of the market, over the forecast period. For instance, in July 2021, Novasep, provider of pharmaceutical and biopharmaceutical technologies, announced the signing of a manufacturing services agreement with Exelixis, a commercially successful, oncology-focused U.S. biotechnology company, for the cGMP clinical production of XB002, a next-generation tissue factor-targeting antibody-drug conjugate (ADC) for oncology applications.
Key Market Takeaways:
Market players are indulged in inorganic activities, such as acquisitions and this is expected to drive growth of the global HPAPIs and cytotoxic drugs manufacturing market, over the forecast period. For instance, in May 2020, Abbvie Contract Manufacturing (AbbVie Inc.) acquired Allergan Plc., for US$ 63 billion. The acquisition is expected to expand product portfolio and strengthen the company’s position in the HPAPI and cytotoxic drugs manufacturing market.
Among regions, North America is expected to hold a dominant position in the global HPAPIs and cytotoxic drugs manufacturing market over the forecast period, owing to increasing approvals of the products in the region. For instance, in December 2020, Amgen Inc., a multinational biopharmaceutical firm based in the U.S., announced that the U.S. Food and Drug Administration (FDA) had approved RIABNI (rituximab-arrx), a biosimilar of Rituxan (rituximab), for the treatment of adult patients with Non-Hodgkin's lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), and Granulomatosis with Polyangiitis (MPA).
Competitive Landscape:
Key players operating in the global HPAPIs and cytotoxic drugs manufacturing market include Teva Pharmaceutical Industries Ltd., Pfizer, Inc., Lonza Group, CordenPharma International, Evonik Industries AG, Flamma Group, Merck KGaA, CARBOGEN AMCIS, Catalent, Inc., Piramal Enterprises Ltd., AbbVie Inc., Fareva Group, Cerbios-Pharma SA, Novasep, Ajinomoto Bio-Pharma, PCI Pharma Services, Sterling Pharma Solutions, Heraeus Holding, Polpharma Biologics, Helsinn Healthcare SA, Seqens, Cambrex Corporation.
Buy-Now this Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/1312
Market Segmentation:
- Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Origin:
- Chemical-based HPAPIs
- Biologic-based HPAPIs
- Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Manufacturing Location:
- In-house Manufacturing
- Outsourcing
- Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Drug Type:
- Novel HPAPIs
- Generic HPAPIs
- Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Type of Pharmacological Molecule:
- Small Molecules
- Biologics
- Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Application:
- Oncology
- Respiratory
- Ophthalmic Disorders
- Others
- Global HPAPIs and Cytotoxic Drugs Manufacturing Market, By Region:
- North America
- By Country:
- U.S.
- Canada
- By Country:
- Latin America
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- By Country:
- Europe
- By Country:
- U.K.
- Germany
- Italy
- Spain
- France
- Russia
- Rest of Europe
- By Country:
- Asia Pacific
- By Country:
- Australia
- India
- China
- Japan
- ASEAN
- South Korea
- Rest of Asia Pacific
- By Country:
- Middle East
- By Country:
- GCC
- Israel
- Rest of Middle East
- By Country:
- Africa
- By Country/Region:
- South Africa
- Central Africa
- North Africa
- By Country/Region:
- North America
Related Market Intelligence Reports:
Oncology Radiopharmaceuticals Market, by Test Type (Radium-223 dichloride, Sodium iodide I-131, Lobenguane iodine-131, Lutetium-177, Yttrium-90, Fludeoxyglucose F 18, Gallium Citrate Ga 67, Technetium-99m, and Others), by Route of Administration (Oral and Intravenous), by Application (Diagnosis and Treatment), by End User (Diagnostic Centres, Hospitals and Clinics, and Research Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
North America Respiratory Trainer Market, by Product Type (Resistance Training Devices, and Endurance Training Devices), by Technique (Inspiratory Muscle Training (Inspiratory Flow Resistive Loading and Inspiratory Pressure Threshold Loading), Expiratory Muscle Training, and Combination of Both), by Disease Indication (Asthma, Chronic Obstructive Pulmonary Disease, and Others), by End User (Children and Adults), and by Country (U.S. and Canada) - Size, Share, Outlook, and Opportunity Analysis, 2021 - 2028
About Us:
Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having sales office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan. Our client base includes players from across various business verticals in over 57 countries worldwide. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
